NKTR Nektar Therapeutics

+1  (3%)
Previous Close 18.61
Open 18.80
Price To book 32.37
Market Cap 2.94B
Shares 153,831,000
Volume 3,706,213
Short Ratio 5.79
Av. Daily Volume 2,056,640

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2017.
Cipro DPI
Phase 3 data released March 20, 2017 - endpoints met.
Lower back pain
Phase 1/2 initial data due at ASCO investor event June 3, 2017. Abstract 2545 (June 5 poster).
Solid tumors - cancer
Phase 3 data due mid-2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 3 data released December 12, 2016 - primary endpoint not met.

Latest News

  1. Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting
  2. How Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain Medicine
  3. Can Drugmakers Cure the Opioid Crisis?
  4. Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology
  5. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  6. Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue?
  7. 3 of the Best & Worst Performing Drug Stocks of Q1
  8. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
  9. Cramer's lightning round: If we get two rate hikes, this stock's a good buy
  10. 3 Revolutionary Drugs for Chronic Pain
  11. Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out
  12. Harry Boxer’s five technology and biotechnology stocks to watch
  13. Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders
  14. Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll explore
  15. Could Nektar Therapeutics Be Worth More?
  16. Nektar Therapeutics (NKTR): Here’s What Just Happened
  17. Nektar's Pain Drug Positive in Phase III Study; Shares Gain
  18. Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News
  19. After-hours buzz: ESPR, NKTR, MMSI & more
  20. Biotech Hits 11-Year High On Potential To Dethrone Oxycodone